Evidence map›Paper›PMID 41465544›Full record

ArticleInternational journal of molecular sciences2025

Integrative Analysis of miR-21, PTEN, and Immune Signatures in Colorectal Cancer.

Yu-Ting Yen, Chen-I Hsu, Yee-Chun Chen, Shih-Chang Tsai

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yu-Ting YenInstitute of Translational Medicine and New Drug Development, School of Medicine, China Medical University, No. 91, Xueshi Road, Taichung 40402, Taiwan.
Chen-I HsuDepartment of Biological Science and Technology, China Medical University, No. 100, Sec. 1, Jing-Mao Road, Taichung 406040, Taiwan.
Yee-Chun ChenNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, R1-7F, No. 35, Keyan Road, Zhunan 35053, Miaoli County, Taiwan.ORCID 0000-0002-1816-9010
Shih-Chang TsaiDepartment of Biological Science and Technology, China Medical University, No. 100, Sec. 1, Jing-Mao Road, Taichung 406040, Taiwan.ORCID 0000-0001-9018-607X

Funding

China Medical University, Taiwan CMU112-N-11Ministry of Science and Technology, Taiwan MOST 106-2314-B-039-046National Science and Technology Council, Taiwan NSTC 112-2320-B-039-007-MY2National Science and Technology Council, Taiwan NSTC 113-2314-B-039-065
6 · The paper itself

Abstract

Colorectal cancer (CRC) remains a major cause of cancer-related mortality worldwide. While immune checkpoint blockade (ICB) has transformed cancer therapy, its clinical benefit in CRC is often limited by an immune-excluded tumor microenvironment (TME). MicroRNA-21-5p (miR-21-5p) is a well-established oncomiR in CRC; however, its role in immune resistance remains incompletely elucidated. In this study, we explored the potential immunoregulatory role of miR-21-5p in CRC by integrating transcriptomic profiling of TCGA-COAD and TCGA-READ cohorts with experimental validation of its target PTEN in CRC cell models. MiR-21-5p was markedly upregulated in tumors compared with adjacent normal tissues and was associated with reduced infiltration of CD8

Indexed as

Colorectal NeoplasmsMicroRNAsPTEN PhosphohydrolaseCell Line, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansSignal TransductionTranscriptomeTumor MicroenvironmentMicroRNAsMIRN21 microRNA, humanPTEN PhosphohydrolasePTEN protein, humancolorectal cancerimmune evasionimmune infiltrationmiR-21-5pPI3K/AKT signalingPTEN

Identifiers

PMID41465544
PMCPMC12732930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.